
Surrozen (SRZN) Stock Forecast & Price Target
Surrozen (SRZN) Analyst Ratings
Bulls say
Surrozen is a promising bio-technology company with strong potential for success in the treatment of retinal diseases. Their product candidates, including SZN-8141 and SZN-413, have shown positive preclinical results in stimulating Wnt signaling, promoting retinal vessel regrowth, and reducing vascular leakage. With continued progress in their clinical development and validation from their strategic partner Boehringer Ingelheim, we view Surrozen as an attractive investment opportunity. However, potential risks to consider are unexpected toxicities or failures in clinical trials and the need for substantial financing.
Bears say
Surrozen is a clinical-stage biotech company developing novel therapeutics in severe eye disease and other organs with a focus on Wnt signaling pathway, a mediator of tissue repair. While their recent milestone and financial updates are promising, there are still many important questions on how their therapies will be differentiated and incorporated into treatment plans. Additionally, their cash reserves may not be enough to support the initial studies for their lead product candidates, and their success in preclinical studies may not guarantee success in clinical trials.
This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.
Surrozen (SRZN) Analyst Forecast & Price Prediction
Start investing in Surrozen (SRZN)
Order type
Buy in
Order amount
Est. shares
0 shares